A detailed history of Hudson Bay Capital Management LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 28,000 shares of ABBV stock, worth $5.74 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
28,000
Previous 129,600 78.4%
Holding current value
$5.74 Million
Previous $25.6 Million 80.56%
% of portfolio
0.02%
Previous 0.12%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$164.99 - $203.87 $7.41 Million - $9.15 Million
-44,897 Reduced 59.86%
30,103 $5.35 Million
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $7.37 Million - $8.97 Million
45,000 Added 150.0%
75,000 $14.8 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $4.64 Million - $5.42 Million
30,000 New
30,000 $5.15 Million
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $16 Million - $18.6 Million
-120,000 Reduced 36.3%
210,552 $31.4 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $29.5 Million - $36.7 Million
222,552 Added 206.07%
330,552 $44.5 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $11.9 Million - $13.7 Million
82,000 Added 315.38%
108,000 $17.2 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $24.1 Million - $28.9 Million
-174,000 Reduced 87.0%
26,000 $4.2 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $26.8 Million - $30.8 Million
200,000 New
200,000 $26.8 Million
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $944,700 - $1.14 Million
-15,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $985,500 - $1.26 Million
15,000 New
15,000 $1.09 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $362B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.